Abstract
Plasma tumour DNA (ptDNA) levels on treatment are associated with response in a variety of cancers. However, the role of ptDNA in prostate cancer monitoring remains largely unexplored. Here we characterised on-treatment ptDNA dynamics and evaluated its potential for early assessment of therapy efficacy for metastatic castration-resistant prostate cancer (mCRPC). Between 2011 and 2016, 114 sequential plasma samples from 43 mCRPC abiraterone-treated patients were collected. Targeted next-generation sequencing was performed to determine ptDNA fraction. ptDNA progressive disease was defined as a rise in the fraction compared to the pre-treatment. A ptDNA rise in the first on-treatment sample (interquartile range (IQR) 2.6-3.7 months) was significantly associated with increased risk of early radiographic or any prostate-specific antigen (PSA) rise (odds ratio (OR) = 15.8, 95% confidence interval (CI) 3.5-60.2, p = 0.0002 and OR = 6.0, 95% CI 1.6-20.0, p = 0.01, respectively). We also identified exemplar cases that had a rise in PSA or pseudoprogression secondary to bone flare but no rise in ptDNA. In an exploratory analysis, initial ptDNA change was found to associate with the duration of response to prior androgen deprivation thera...Continue Reading
References
Apr 8, 2010·Science Translational Medicine·Rebecca J LearyVictor E Velculescu
Dec 1, 2012·Science Translational Medicine·Rebecca J LearyVictor E Velculescu
Apr 9, 2013·Nature·Muhammed MurtazaNitzan Rosenfeld
Jul 8, 2014·Clinical Genitourinary Cancer·Salvatore L BurgioUgo De Giorgi
Sep 19, 2014·Science Translational Medicine·Suzanne CarreiraGerhardt Attard
Nov 6, 2015·Science Translational Medicine·Alessandro RomanelGerhardt Attard
Feb 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group 3
May 6, 2016·JAMA Oncology·Alexander W WyattKim N Chi
Apr 22, 2017·The Prostate·Vincenza ConteducaUgo De Giorgi
May 5, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V ConteducaG Attard
Jan 26, 2018·Cancer Discovery·Matti AnnalaKim N Chi
Nov 11, 2018·Prostate Cancer and Prostatic Diseases·Enrique González-BillalabeitiaGerhardt Attard
Jan 9, 2019·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 15, 2019·European Urology·Gillian VandekerkhoveAlexander W Wyatt
Feb 18, 2019·European Urology Focus·Alastair DaviesHimisha Beltran
Mar 13, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S HrebienN Turner
May 7, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emil ChristensenLars Dyrskjøt
Mar 10, 2020·The Journal of Clinical Investigation·Anjui WuGerhardt Attard
Citations
Jan 17, 2021·Prostate Cancer and Prostatic Diseases·Takayuki SumiyoshiAlexander W Wyatt
Mar 13, 2021·Therapeutic Advances in Medical Oncology·Vincenza ConteducaUgo De Giorgi
Apr 2, 2021·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A JayaramG Attard
Apr 10, 2021·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M AnnalaK N Chi
May 28, 2021·Expert Review of Molecular Diagnostics·Vincenza ConteducaUgo De Giorgi
Jul 15, 2021·Nature Cancer·Joaquin MateoHimisha Beltran
Aug 18, 2021·IScience·Eszter LakatosTrevor A Graham
Oct 5, 2021·International Journal of Cancer. Journal International Du Cancer·Vincenza ConteducaUgo De Giorgi
Oct 18, 2021·Molecular Oncology·Vincenza ConteducaUgo De Giorgi